- Home
- ABAT vs ZURA Comparison
ABAT vs ZURA Comparison
Compare ABAT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- ZURA
- Stock Information
- Founded
- ABAT 2011
- ZURA 2022
- Country
- ABAT United States
- ZURA United States
- Employees
- ABAT N/A
- ZURA N/A
- Industry
- ABAT Metal Mining
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABAT Basic Materials
- ZURA Health Care
- Exchange
- ABAT Nasdaq
- ZURA Nasdaq
- Market Cap
- ABAT 87.2M
- ZURA 69.9M
- IPO Year
- ABAT N/A
- ZURA N/A
- Fundamental
- Price
- ABAT $1.68
- ZURA $1.31
- Analyst Decision
- ABAT
- ZURA Buy
- Analyst Count
- ABAT 0
- ZURA 7
- Target Price
- ABAT N/A
- ZURA $14.33
- AVG Volume (30 Days)
- ABAT 2.7M
- ZURA 708.2K
- Earning Date
- ABAT 05-16-2025
- ZURA 08-08-2025
- Dividend Yield
- ABAT N/A
- ZURA N/A
- EPS Growth
- ABAT N/A
- ZURA N/A
- EPS
- ABAT N/A
- ZURA N/A
- Revenue
- ABAT $1,857,877.00
- ZURA N/A
- Revenue This Year
- ABAT $31,748.62
- ZURA N/A
- Revenue Next Year
- ABAT N/A
- ZURA N/A
- P/E Ratio
- ABAT N/A
- ZURA N/A
- Revenue Growth
- ABAT N/A
- ZURA N/A
- 52 Week Low
- ABAT $0.73
- ZURA $0.97
- 52 Week High
- ABAT $4.11
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- ABAT 56.30
- ZURA 59.63
- Support Level
- ABAT $1.78
- ZURA $1.00
- Resistance Level
- ABAT $2.04
- ZURA $1.45
- Average True Range (ATR)
- ABAT 0.19
- ZURA 0.10
- MACD
- ABAT 0.03
- ZURA 0.03
- Stochastic Oscillator
- ABAT 56.47
- ZURA 68.89
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.